FDA Approves Extension of the Indication for Accrufer to Include Children 10 Years and Older with Iron Deficiency

Dec 28, 2025 - 21:00
 0  3
London, UK, 22 December 2025: Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, announces that the US Food and Drug Administration (FDA), following a priority review of the clinical...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0